SCHEMBL1009064

SCHEMBL1009064

CCCC(F)[SiH](C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1258385 0.73
SCHEMBL15091520 0.69
SCHEMBL9715114 0.69
SCHEMBL3838381 0.67 TSHR (0.32)
SCHEMBL1030544 0.66 TSHR (0.33)
SCHEMBL10665033 0.65
SCHEMBL45375 0.65
SCHEMBL28629964 0.65
SCHEMBL27815921 0.62
SCHEMBL1535422 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1404446-A2 CATALYST COMPRISING CHROMIUM AND A LIGAND COMPRISING A SUBSTITUTED CYCLOPENTADIENE AND ITS USE FOR TRIMERISING OLEFINS Sasol Technology (Proprietary) Limited (ZA) 2004-04-07 EP claimed
WO-2003004158-A2 CATALYST COMPRISING CHROMIUM AND A LIGAND COMPRISING A SUBSTITUTED CYCLOPENTADIENE AND ITS USE FOR TRIMERISING OLEFINS SASOL TECHNOLOGY (PROPRIETARY) LIMITED (ZA) 2003-01-16 WO claimed
EP-4188924-A1 ANTAGONIST COMPOUNDS Adorx therapeutics Limited (GB) 2023-06-07 EP disclosed
EP-4003516-A1 PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS TMEM16A LIMITED (GB) 2022-06-01 EP disclosed
WO-2022023772-A1 ANTAGONIST COMPOUNDS AdoRx Therapeutics Limited (GB) 2022-02-03 WO disclosed
WO-2021014166-A1 PYRIDINE DERIVATIVES AS TMEM16A MODULATORS FOR USE IN THE TREATMENT OF RESPIRATORY CONDITIONS Enterprise Therapeutics Limited (GB) 2021-01-28 WO disclosed
WO-2020161052-A1 ORGANIC SEMICONDUCTING POLYMERS MERCK PATENT GMBH (DE) 2020-08-13 WO disclosed
EP-2989092-A1 QUINAZOLINONE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS Astex Therapeutics Ltd. (GB) 2016-03-02 EP disclosed
WO-2014174307-A1 QUINAZOLINONE DERIVATIVES USEFUL AS FGFR KINASE MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2014-10-30 WO disclosed
EP-2496583-A1 DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES Pfizer Inc. (US) 2012-09-12 EP disclosed
EP-2321265-A1 INOSITOL AND TREHALOSE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES COMPRISING THE SAME Postech Academy-Industry Foundation (KR) 2011-05-18 EP disclosed
WO-2007067612-A1 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2, 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS NOVARTIS AG (CH) 2007-06-14 WO disclosed
WO-2007067614-A1 l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS NOVARTIS AG (CH) 2007-06-14 WO disclosed
WO-2007056170-A2 PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES BAYER HEALTHCARE AG (DE) 2007-05-18 WO disclosed
WO-2007041257-A2 SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2007-04-12 WO disclosed
WO-2007000445-A1 GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-04 WO disclosed
WO-2006108842-A1 GLUCOPYRANOSYL-SUBSTITUTED (HETEROARYLOXY-BENZYL)-BENZENE DERIVATIVES AS SGLT INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-10-19 WO disclosed
WO-2006057870-A1 POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2006-06-01 WO disclosed
EP-1492780-A1 5-SUBSTITUTED 1,1-DIOXO-[1,2,5]THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS Novartis AG (CH) 2005-01-05 EP disclosed
WO-2003082841-A1 5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS NOVARTIS AG (CH) 2003-10-09 WO disclosed